YesPlexusDx protocols typically begin with the lowest effective starting dose (0.25 mg for injections), which produces gentler, slower-onset side effects
Approval timelines depend on trial outcomes and regulatory review
Bariatric Surgery as an Alternative to Semaglutide In addition to weight loss medication options, some patients may consider bariatric surgery as a long-term solution for obesity and related conditions
Neither injectable nor oral formats guarantee specific weight loss amounts for any individual patient
Burning or stinging Some users report a burning or stinging sensation during or immediately after injection
Prior Authorization Criteria for Michigan Medicaid To qualify for Wegovy coverage under Michigan Medicaid, a prescriber typically must document: BMI 30 kg/m, or BMI 27 kg/m with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea) Participation in or referral to a behavioral weight-management program Absence of contraindications listed in the FDA label, including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (FDA prescribing information) Prescriber attestation that the patient has attempted lifestyle modification for at least 90 days PA approvals are typically granted for six months initially, with renewal requiring documented weight loss of at least 5% body weight
